Abstracts tagged "Adverse events"

Abstract Number: 448 • 2018 ACR/ARHP Annual Meeting
Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice
Sandip Chaugai¹, Alyson Dickson², Megan Shuey², QiPing Feng², Katherine Barker², James Luther², C. Michael Stein³ and Cecilia P. Chung³, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Tizanidine, a muscle relaxant widely used for musculoskeletal pain, can lower blood pressure and is metabolized by the cytochrome P450 1A2 (CYP1A2). As a…
Abstract Number: 1919 • 2018 ACR/ARHP Annual Meeting
Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
Cecilia P. Chung¹, S. Todd Callahan², William Cooper², William Dupont³, Katherine Murray¹, Andrew Franklin⁴, Kathi Hall⁵, Judith A. Dudley⁵, C. Michael Stein¹ and Wayne Ray⁵, ¹Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ⁴Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, ⁵Health Policy, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hydrocodone, codeine, oxycodone, and tramadol are frequently prescribed for moderate pain in adolescents. However, pharmacokinetic and pharmacodynamic differences between these short-acting opioids could affect…
Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Lisa Ehlers¹, Johan Askling², Johannes W. J. Bijlsma³, Maria C. Cid⁴, Maurizio Cutolo⁵, Bhaskar Dasgupta⁶, Christian Dejaco^7,8, William G Dixon⁹, Nils Feltelius^10,11, Axel Finckh¹², Kate Gilbert¹³, Sarah Mackie¹⁴, Alfred Mahr¹⁵, Eric L. Matteson¹⁶, Lorna Neill¹⁷, Carlo Salvarani^18,19, Wolfgang A. Schmidt²⁰, Anja Strangfeld²¹, Ronald van Vollenhoven²² and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Barcelona, Barcelona, Spain, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Rheumatology, Hospital of Bruneck, Bruneck, Italy, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ¹⁰Medical Products Agency, Uppsala, Sweden, ¹¹Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, ¹²University Hospital of Geneva, Geneva, Switzerland, ¹³Patient Representative from PMRGCAuk, London, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ¹⁵Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, ¹⁶Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, ¹⁸Università di Modena e Reggio Emilia, Modena, Italy, ¹⁹Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²⁰Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
Abstract Number: 2139 • 2018 ACR/ARHP Annual Meeting
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Mateo Mejia Saldarriaga¹, Ivan Emil Ramirez de Oleo¹ and Beverly Johnson^2,3, ¹Internal Medicine, Jacobi Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Clinical hemolysis and severity…
Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Lene Dreyer¹, Tine Iskov Kopp², Rikke Kart Jacobsen³, Melinda Magyari², Else Helene Ibfelt³, Henning Locht⁴, Finn Thorup Sellebjerg², Dorte Vendelbo Jensen⁵ and René Cordtz⁶, ¹Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ²Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Dilpreet Singh¹, Leila Muhieddine², Douglas Einstadter³ and Stanley Ballou⁴, ¹Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁴Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…
Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
Abstract Number: 1963 • 2017 ACR/ARHP Annual Meeting
Association of Corticosteroid Exposure with Ophthalmologic Complications and Systemic Adverse Events in Non-Infectious Uveitis Patients Using Administrative Claims in the United States
Nisha Acharya¹, Keith A. Betts², Oscar Patterson-Lomba², Arijit Ganguli³, Sophie Schonfeld² and Jenny Griffith³, ¹University of California San Francisco, San Francisco, CA, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Noninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders associated with significant visual impairment. Corticosteroids (CS) are typically the first-line drug therapy for…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 2119 • 2017 ACR/ARHP Annual Meeting
Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Emma Mitchell¹, Peter Lau², Chloe Khoo², Kortnye Smith², Benjamin Brady², Mark Shackleton², Grant McArthur², Ian Wicks^1,3,4 and Shahneen Sandhu², ¹Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, ²Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, ³Medicine, University of Melbourne, Melbourne, Australia, ⁴Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia
Background/Purpose: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung…
Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Noha Abdel-Wahab^1,2, Mohsin Shah¹, Maria A. Lopez-Olivo¹ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Mohsin Shah¹, Jean Tayar¹, Noha Abdel-Wahab^1,2 and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
Abstract Number: 2222 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Respiratory Depression in Patients Treated with Opioids for Non-Malignant Pain
Meghna Jani, Kamilla Kopec-Harding, Mark Lunt and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid use for non-cancer pain has increased considerably over the last 30 years. The U.S. Food and Drug Administration announced several boxed warnings in…
Abstract Number: 2256 • 2017 ACR/ARHP Annual Meeting
Temporal Increases in Side Effect Concerns of Osteoporosis Medications Among Women with Previous Fractures
Maria I. Danila¹, Elizabeth J. Rahn², Amy S. Mudano¹, Ryan Outman³, Peng Li⁴, David T. Redden⁴, Fred A. Anderson⁵, Susan L. Greenspan⁶, Andrea Z. LaCroix⁷, Jeri W. Nieves⁸, Stuart L. Silverman⁹, E.S. Siris¹⁰, Nelson B. Watts¹¹, Sigrid Ladores¹², Karen Meneses¹², Jeffrey R. Curtis¹³ and Kenneth Saag¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Group Health Cooperative, Seattle, WA, ⁸Helen Hayes, West Haverstraw, NY, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Columbia University Medical Center, New York, NY, ¹¹University of Cincinnati, Cincinnati, OH, ¹²Nursing, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: High-consequence, albeit rare, adverse side effects of osteoporosis medication raise patients’ risk perceptions and contribute to non-adherence. In the past decade, fears of osteonecrosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].